(Q42932507)

11 November 2017

title

Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets (English)

1 reference

11 November 2017

4

1 reference

11 November 2017

S L Schadinger

1

1 reference

11 November 2017

J H H Lin

series ordinal

2

1 reference

11 November 2017

M Garand

series ordinal

3

1 reference

11 November 2017

publication date

1 November 2010

1 reference

Journal of Thrombosis and Haemostasis

11 November 2017

published in

1 reference

11 November 2017

volume

8

1 reference

11 November 2017

issue

11

1 reference

11 November 2017

page(s)

2523-2529

1 reference

Role of cellular elements in thrombus formation and dissolution

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Structure of fibrin: impact on clot stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Fibrinolysis at the fluid-solid interface of thrombi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Purification and characterization of a new arginine carboxypeptidase in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Pro-carboxypeptidase R cleaves bradykinin following activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Activation and characterization of procarboxypeptidase B from human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Development of a genotype 325-specific proCPU/TAFI ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.04024.X

10.1111/J.1538-7836.2010.04024.X

21 January 2018

Identifiers

DOI

1 reference

11 November 2017

1 reference